Member of NITI Aayog, Dr. VK Paul on April 19 said that the production of Remdesivir would be aimed at scaling up to 76 lakh vials per month.
Dr. VK Paul said, "Air-borne transmission is more prevalent than surface transmission.
As for Remdesivir production, it had gone down but now from 27 lakh vials/month, it has been scaled up to 40 lakh vials/month while aiming for 76 lakh vials/month."
